Leállítva4. fázis
Use of CXCL9 as a Biomarker of Acthar Efficacy
Megadott ok: sponsor closed study down
A legfontosabb adatok
- Hol
- San Francisco (Egyesült Államok)A helyszín megnézése
- Fázis
- 4. fázis
Helyszínek itt: Egyesült Államok
- University of California San FranciscoSan Francisco, Egyesült ÁllamokNo longer taking part
A vizsgálat adatai
- Ki végzi
- University of California, San Francisco
- Azonosító
- NCT02523092
- A regiszteradat frissítve
- 2026. április 30.
- Eredeti leírás
The objective is this study is to test whether use of Acthar gel in the context of sarcoidosis will lead to improved symptoms and lung function and correlate with decreased levels of predictive blood biomarkers, like chemokine ligand 9 (CXCL9).A teljes eredeti leírásKevesebb
The objective is this study is to test whether use of Acthar gel in the context of sarcoidosis will lead to improved symptoms and lung function and correlate with decreased levels of predictive blood biomarkers, like chemokine ligand 9 (CXCL9).
Bevonási feltételek: Biopsy-proven diagnosis of sarcoidosis with demonstrated pulmonary involvement; Refractoriness to or intolerance of immunosuppressive agents like prednisone or methotrexate.
Kizáró feltételek: Recent surgery; Cancer; Chronic infections (e.g. tuberculosis, viral, fungal, bacterial); Inflammatory conditions; Coexisting lung disease; Congestive heart failure; Uncontrolled hypertension; Smoking; Active peptic ulcers; Osteoporosis.